Ultrasound-assisted vs Landmark Based Intrathecal Administration of Nusinersen
Muscular Atrophy, Spinal, Ultrasound
About this trial
This is an interventional treatment trial for Muscular Atrophy, Spinal
Eligibility Criteria
Inclusion Criteria:
- SMA adult patients
Exclusion Criteria:
- coagulation defects;
- medication with anticoagulant;
- infection in puncture site;
- high intracranial pressure
Sites / Locations
- IRCCS Policlinico Agostino GemelliRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
US-assisted nusinersen administration
landmark based nusinersen administration
A paramedian sagittal oblique view will be used to identify with ultrasound specific lumbar interspaces. After local anesthesia the spinal needle will be used to identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.
The desired intervertebral space will be first identified by manual palpation of surface landmarks and marked on the skin. After local anesthesia the spinal needle will be usedto identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.